普洛药业：产品“头孢地尼胶囊”取得注册证

Group 1 - Prolo Pharmaceutical Co., Ltd. announced that its subsidiary, Zhejiang Prolo Kangyu Pharmaceutical Co., Ltd., received a drug registration certificate for Cefdinir capsules from the National Medical Products Administration [1] - For the first half of 2025, Prolo Pharmaceutical's revenue composition is 99.6% from the pharmaceutical industry and 0.4% from other businesses [1] - As of the report date, Prolo Pharmaceutical has a market capitalization of 18.1 billion yuan [1]